隶属于 friedberg mercantile group ltd. /friedberg family/
Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer in April 2001 and is headquartered in Rochester, NY.
相关临床试验
7
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1997
进行中（未招募）
1
14.3%
已完成
6
85.7%
暂无批准数据
- Vaccinex will present new biomarker data from its Phase 1b/2 SIGNAL-AD study at the Alzheimer's Association International Conference in London on July 13, 2026. - The data support plans for an enlarged randomized Phase 2b "SIGNAL-AD2" trial of pepinemab, a SEMA4D-blocking monoclonal antibody, in early Alzheimer's disease. - Pepinemab targets a novel mechanism involving reactive astrocytes and neuroinflammation, distinct from amyloid-focused approaches. - The SIGNAL-AD study was funded in part by the Alzheimer's Association and the Alzheimer's Drug Discovery Foundation.
- Vaccinex announced a $60 million revenue sharing agreement with Pepinemab Development Venture to fund an enlarged Phase 2b clinical trial of pepinemab for Alzheimer's disease treatment. - The anti-SEMA4D antibody pepinemab demonstrated promising results in early trials, blocking harmful brain inflammation and preserving vascular integrity while reducing disease-related proteins in cerebrospinal fluid. - Recent genetic research identified the SEMA4D-PLXNB1 signaling pathway as a key regulator of Ast10 astrocytes, which correlate with cognitive decline in Alzheimer's patients. - Pepinemab treatment reduced Ast10 cell representation in the brain and appeared to slow cognitive decline compared to placebo controls in previous studies.
- Vaccinex will present new clinical data at ASCO 2025 showing that neoadjuvant treatment with pepinemab induces mature tertiary lymphoid structures that correlate with improved pathologic response in head and neck cancer patients. - The SEMA4D-blocking antibody pepinemab demonstrates potential to transform immunologically "cold" tumors into "hot" immune centers by enhancing dendritic cell function and T cell interactions within organized immune structures. - Clinical studies reveal that pepinemab combination therapy enhanced tertiary lymphoid structure maturity and correlated with longer recurrence-free survival in metastatic melanoma patients without compounding toxicities. - The drug candidate shows promise for treating HPV-negative head and neck cancers and other immunologically resistant tumors that typically respond poorly to checkpoint inhibitor therapy alone.
• Vaccinex will delist from Nasdaq on March 17 after failing to meet equity requirements, despite reporting positive Phase II results for its lead Alzheimer's candidate pepinemab in 2024. • The company's market capitalization has fallen to approximately $2.5 million, with cash reserves of just $2.9 million as of September 2024, reflecting financial challenges despite initial success raising $40 million in its 2018 IPO. • Vaccinex plans to continue developing pepinemab for both Alzheimer's disease and oncology indications through partnerships, including ongoing collaborations with MSD and Merck KGaA for cancer trials.
• Eisai's E2814, an anti-tau drug, showed promise in reducing disease biomarkers in a Phase 1 trial involving participants with genetic Alzheimer's, warranting further studies. • Roche's trontinemab demonstrated effective amyloid reduction at high doses with a lower incidence of ARIA compared to other anti-amyloid antibodies in a Phase 1/2 trial. • UCB's beprenemab, a tau-targeting antibody, failed to slow cognitive decline in a Phase 2 trial, leading Roche to terminate their development and commercialization agreement. • Gene therapy LX001 from Lexeo Therapeutics showed early signs of success by increasing ApoE2 protein production and stabilizing amyloid levels in an ongoing Phase 1/2 study.
- Vaccinex will present new data from its SIGNAL-AD Phase 1b/2 trial of pepinemab for Alzheimer's disease at the CTAD conference. - The study evaluates pepinemab's impact on cognitive decline and biomarkers of disease progression by blocking SEMA4D. - Preclinical models suggest pepinemab may have beneficial effects on brain vasculature, potentially avoiding toxicity in Alzheimer’s disease. - Pepinemab is designed to block SEMA4D, aiming to prevent damaging inflammation and slow disease progression in the brain.
